litlas
Log inCreate account

Christopher J. Sweeney

Active 2000–2025

165
Papers
26,655
Citations
87
h-index
158
i10-index

Citations

Citations per year for Christopher J. Sweeney2001: 7 citations2002: 27 citations2003: 45 citations2004: 54 citations2005: 57 citations2006: 70 citations2007: 61 citations2008: 61 citations2009: 62 citations2010: 70 citations2011: 60 citations2012: 71 citations2013: 73 citations2014: 95 citations2015: 116 citations2016: 128 citations2017: 155 citations2018: 213 citations2019: 788 citations2020: 944 citations2021: 1,063 citations2022: 879 citations2023: 722 citations2024: 1,262 citations2025: 564 citations2026: 22 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,705 citing papers, 24.7% of this breakdownChina: 885 citing papers, 8.1% of this breakdownUnited Kingdom: 728 citing papers, 6.6% of this breakdownItaly: 646 citing papers, 5.9% of this breakdownGermany: 579 citing papers, 5.3% of this breakdownCanada: 542 citing papers, 5% of this breakdownFrance: 466 citing papers, 4.3% of this breakdownSpain: 378 citing papers, 3.5% of this breakdownJapan: 365 citing papers, 3.3% of this breakdownAustralia: 358 citing papers, 3.3% of this breakdownSwitzerland: 309 citing papers, 2.8% of this breakdownNetherlands: 297 citing papers, 2.7% of this breakdown
0%24.7%Other 24.5%

Institutions

Fields

  • Medicine67.7%
  • Biochemistry, Genetics and Molecular Biology23.5%
  • Immunology and Microbiology2.3%
  • Agricultural and Biological Sciences1.2%
  • Computer Science1.2%
  • Engineering0.7%
  • Other3.4%

Topics

  • Prostate Cancer Treatment and Research12.8%
  • Prostate Cancer Diagnosis and Treatment7.6%
  • Radiopharmaceutical Chemistry and Applications3.1%
  • Cancer, Lipids, and Metabolism2.7%
  • Cancer Immunotherapy and Biomarkers2.4%
  • Cancer Genomics and Diagnostics2.4%
  • Other69%

Coauthors

All papers

Open in search
  1. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

    Authors: Christopher J. Sweeney, Yu‐Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard, Mario A. Eisenberger, Yu-Ning Wong, Noah M. Hahn, Manish Kohli, Matthew M. Cooney, Robert Dreicer, Nicholas J. Vogelzang, Joel Picus, Daniel H. Shevrin, Maha Hussain, Jorge A. García, Robert S. DiPaola - New England Journal of Medicine 2015 cited by 2,835

  2. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

    Authors: Ian D. Davis, Andrew Martin, Martin R. Stockler, Stephen Begbie, Kim N., Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy Hague, Lisa G. Horvath, Anthony M. Joshua, Nicola Jane Lawrence, Gavin Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott North, Francis Parnis, Wendy R. Parulekar, David Pook, M. Neil Reaume, Shahneen Sandhu, Alvin Tan, Thean Hsiang Tan, Alastair Thomson, Emily Tu, Francisco Vera-Badillo, Scott Williams, Sonia Yip, Alison Y. Zhang, Robert Zielinski, Christopher J. Sweeney - New England Journal of Medicine 2019 cited by 1,593

  3. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

    Authors: Christos E. Kyriakopoulos, Yu‐Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard, Noah M. Hahn, Daniel H. Shevrin, Robert Dreicer, Maha Hussain, Mario A. Eisenberger, Manish Kohli, Elizabeth R. Plimack, Nicholas J. Vogelzang, Joel Picus, Matthew M. Cooney, Jorge A. García, Robert S. DiPaola, Christopher J. Sweeney - Journal of Clinical Oncology 2018 cited by 1,106

  4. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

    Authors: Funda Meric‐Bernstam, Herbert I. Hurwitz, Kanwal Raghav, Robert R. McWilliams, Marwan Fakih, Ari M. Vanderwalde, Charles Swanton, Razelle Kurzrock, Howard A. Burris, Christopher J. Sweeney, Ron Bose, David R. Spigel, Mary Beattie, Steven Blotner, Alyssa Stone, Katja Schulze, Vaikunth Cuchelkar, John D. Hainsworth - The Lancet Oncology 2019 cited by 564

  5. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

    Authors: Milind Javle, Mitesh J. Borad, Nilofer S. Azad, Razelle Kurzrock, Ghassan K. Abou‐Alfa, Ben George, John D. Hainsworth, Funda Meric‐Bernstam, Charles Swanton, Christopher J. Sweeney, Claire F. Friedman, Ron Bose, David R. Spigel, Yong Wang, Jonathan Levy, Katja Schulze, Vaikunth Cuchelkar, Arisha Patel, Howard A. Burris - The Lancet Oncology 2021 cited by 406

  6. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

    Authors: Christopher J. Sweeney, Sergio Bracarda, Cora N. Sternberg, Kim N., David Olmos, Shahneen Sandhu, Christophe Massard, Nobuaki Matsubara, B. Yа. Alekseev, Francis Parnis, Vagif Atduev, Gary L. Buchschacher, Rustem Gafanov, Luis Corrales, Michael Borre, Daniil Stroyakovskiy, Gustavo Vasconcelos Alves, Evangelos Bournakis, Javier Puente, Marie-Laurence Harle-Yge, Jorge D. Gallo, Geng Chen, Justin Hanover, Matthew Wongchenko, Josep Garcia, Johann S. de Bono - The Lancet 2021 cited by 329

  7. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

    Authors: Thomas Powles, Kobe Yuen, Silke Gillessen, Edward E. Kadel, Dana E. Rathkopf, Nobuaki Matsubara, Charles G. Drake, Karim Fizazi, Josep M. Piulats, Piotr J. Wysocki, Gary L. Buchschacher, B. Yа. Alekseev, Begoña Mellado, Bogusława Karaszewska, Jennifer Doss, Grozdana Rasuo, Asim Datye, Sanjeev Mariathasan, Patrick Williams, Christopher J. Sweeney - Nature Medicine 2022 cited by 242

  8. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial

    Authors: Christopher J. Sweeney, Andrew Martin, Martin R. Stockler, Stephen Begbie, Leanna Cheung, Kim N., Simon Chowdhury, Mark Frydenberg, Lisa G. Horvath, Anthony M. Joshua, Nicola Jane Lawrence, Gavin Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott North, Francis Parnis, Wendy R. Parulekar, David Pook, M. Neil Reaume, Shahneen Sandhu, Alvin Tan, Thean Hsiang Tan, Alastair Thomson, Francisco Vera-Badillo, Scott Williams, Diana Winter, Sonia Yip, Alison Y. Zhang, Robert Zielinski, Ian D. Davis, Ehtesham Abdi, Suzanne Allan, Patricia Bastick, Stephen Begbie, Robert Blum, Karen Briscoe, Daniel Brungs, Sean Bydder, Bala Renuka Chittajallu, Michelle R. Cronk, Katharine Cuff, Ian D. Davis, Anthony Dowling, Mark Frydenberg, M. C. George, Lisa G. Horvath, Elizabeth Hovey, Anthony M. Joshua, Narayan Karanth, Ganessan Kichenadasse, Laurence E. Krieger, Gavin Marx, Maitham Mathlum, Louise Nott, Zulfiquer Otty, Francis Parnis, David Pook, Shahneen Sandhu, Sanjeev Sewak, Amanda Gwendolyn Stevanovic, Martin R. Stockler, Aneta Suder, Hsiang Tan, Javier Torres, Simon Troon, Craig Underhill, Andrew Weickhardt, Robert Zielinski, Tahir Abbas, Ghadeer Anan, Chris Booth, H. E. A. Campbell, Kim Chi, Joseph L. Chin, E. Chouinard, Bryan Donnelly, Darrel Drachenberg, Amir Faghih, Antonio Finelli, Sebastién J. Hotte, Krista Noonan, Scott North, Mohammad Rassouli, Neil Reaume, Ricardo Rendon, Fred Saad, Evgeny Sadikov, Éric Vigneault, Paweł Zalewski, John McCaffrey, Ray McDermott, Patrick G. Morris, Miriam O’Connor, Paul Donnellan, Dearbhaile M. O’Donnell, Dearbhaile O'Donnell, Peter C.C. Fong, Alvin Tan, Simon Chowdhury and 13 more - The Lancet Oncology 2023 cited by 188

  9. EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer

    Authors: Katherine L. Morel, Anjali V. Sheahan, Deborah L. Burkhart, Sylvan C. Baca, Nadia Boufaied, Yin Liu, Xintao Qiu, Israel Cañadas, Kevin Roehle, Max Heckler, Carla Calagua, Huihui Ye, Constantia Pantelidou, Phillip M. Galbo, Sukanya Panja, Antonina Mitrofanova, Scott Wilkinson, Nichelle C. Whitlock, Shana Y. Trostel, Anis Hamid, Adam S. Kibel, David A. Barbie, Atish D. Choudhury, Mark M. Pomerantz, Christopher J. Sweeney, Henry W. Long, David J. Einstein, Geoffrey I. Shapiro, Stephanie K. Dougan, Adam G. Sowalsky, Housheng Hansen He, Matthew L. Freedman, Steven P. Balk, Massimo Loda, David P. Labbé, Brian M. Olson, Leigh Ellis - Nature Cancer 2021 cited by 241

  10. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    Authors: Silke Gillessen, Alberto Bossi, Ian D. Davis, Johann S. de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, Neal D. Shore, Eric J. Small, Matthew R. Smith, Christopher J. Sweeney, Bertrand Tombal, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Alberto Briganti, Robert G. Bristow, Muhammad Bulbul, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N., Simon Chowdhury, Caroline S. Clarke, Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Ross Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Dan George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raja Leibowitz, Christopher Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Amee Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki and 18 more - European Journal of Cancer 2023 cited by 157

  11. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

    Authors: John D. Hainsworth, Funda Meric‐Bernstam, Charles Swanton, Herbert I. Hurwitz, David R. Spigel, Christopher J. Sweeney, Howard A. Burris, Ron Bose, Bongin Yoo, Alisha Stein, Mary Beattie, Razelle Kurzrock - Journal of Clinical Oncology 2018 cited by 505

  12. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer

    Authors: Wanling Xie, Meredith M. Regan, Marc Buyse, Susan Halabi, Philip W. Kantoff, Oliver Sartor, Howard R. Soule, Noel W. Clarke, Laurence Collette, James J. Dignam, Karim Fizazi, Wendy R. Paruleker, Howard M. Sandler, Matthew R. Sydes, Bertrand Tombal, Scott Williams, Christopher J. Sweeney, on behalf of the ICECaP Working Group - Journal of Clinical Oncology 2017 cited by 434

  13. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer

    Authors: Anis Hamid, Kathryn P. Gray, Grace Shaw, Laura E. MacConaill, Carolyn Evan, Brandon Bernard, Massimo Loda, Niall M. Corcoran, Eliezer M. Van Allen, Atish D. Choudhury, Christopher J. Sweeney - European Urology 2018 cited by 269

  14. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    Authors: Silke Gillessen, Alberto Bossi, Ian D. Davis, Johann S. de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, Neal D. Shore, Eric J. Small, Matthew R. Smith, Christopher J. Sweeney, Bertrand Tombal, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Alberto Briganti, Robert G. Bristow, Muhammad Bulbul, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N., Simon Chowdhury, Caroline S. Clarke, Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Rosalind A. Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Daniel J. George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia S. Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raya Leibowitz‐Amit, Christopher J. Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Alicia K. Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver A. Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki and 18 more - European Urology 2022 cited by 118

  15. First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer

    Authors: Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, Huan He, Noureen Asghar, Rabbia Siddiqi, Hongfang Liu, Parminder Singh, Daniel S. Childs, Praful Ravi, Syed A. Hussain, M. Hassan Murad, Stephen A. Boorjian, Christopher J. Sweeney, Eliezer M. Van Allen, Alan H. Bryce - JAMA Oncology 2023 cited by 121

  16. Next generation radiotheranostics promoting precision medicine

    Authors: Kelsey L. Pomykala, Boris Hadaschik, Oliver Sartor, Silke Gillessen, Christopher J. Sweeney, Tim Maughan, Michael S. Hofman, Ken Herrmann - Annals of Oncology 2023 cited by 69

  17. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium

    Authors: Silke Gillessen, Nicolas Sauvé, Laurence Collette, Gedske Daugaard, Ronald de Wit, Costantine Albany, A. Tryakin, Karim Fizazi, Olof Ståhl, Jourik A. Gietema, Ugo De Giorgi, Fay Cafferty, Aaron R. Hansen, Torgrim Tandstad, Robert Huddart, Andrea Necchi, Christopher J. Sweeney, Xavier García del Muro, Daniel Yick Chin Heng, Anja Lorch, Michal Chovanec, Eric Winquist, Peter Grimison, Darren R. Feldman, Angelika Terbuch, Marcus Hentrich, Carsten Bokemeyer, Helene F. S. Negaard, Christian D. Fankhauser, Jonathan Shamash, David J. Vaughn, Cora N. Sternberg, Axel Heidenreich, J. Beyer - Journal of Clinical Oncology 2021 cited by 238

  18. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

    Authors: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Alberto Bossi, Robert G. Bristow, Brett S. Carver, Daniel Castellano, Byung Ha Chung, Noel W. Clarke, Gedske Daugaard, Ian D. Davis, Johann S. de Bono, Rodolfo Borges dos Reis, Charles G. Drake, Rosalind A. Eeles, Eleni Efstathiou, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Karim Fizazi, Mark Frydenberg, Martin Gleave, Susan Halabi, Axel Heidenreich, Celestia S. Higano, Nicolas James, Philip W. Kantoff, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Gero Kramer, Chris Logothetis, Fernando Cotait Maluf, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Vedang Murthy, William Oh, Piet Ost, Anwar R. Padhani, Chris Parker, Colin C. Pritchard, Mack Roach, Mark A. Rubin, Charles J. Ryan, Fred Saad, Oliver Sartor, Howard I. Scher, Avishay Sella, Neal D. Shore, Matthew R. Smith, Howard R. Soule, Cora N. Sternberg, Hiroyoshi Suzuki, Christopher J. Sweeney, Matthew R. Sydes, Ian F. Tannock, Bertrand Tombal, R. Valdagni, Thomas Wiegel, Aurelius Omlin - European Urology 2017 cited by 643

  19. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis

    Authors: Sarah Burdett, Liselotte M.S. Boevé, Fiona C. Ingleby, David J. Fisher, Larysa Rydzewska, Claire L. Vale, George van Andel, Noel W. Clarke, Maarten C.C.M. Hulshof, Nicholas D. James, Christopher Parker, Mahesh Parmar, Christopher J. Sweeney, Matthew R. Sydes, Bertrand Tombal, Paul C.M.S. Verhagen, Jayne F. Tierney - European Urology 2019 cited by 320

  20. Current treatment strategies for advanced prostate cancer

    Authors: Kazumasa Komura, Christopher J. Sweeney, Teruo Inamoto, Naokazu Ibuki, Haruhito Azuma, Philip W. Kantoff - International Journal of Urology 2017 cited by 247

  21. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials

    Authors: Claire L. Vale, David J. Fisher, Peter J. Godolphin, Larysa Rydzewska, Jean‐Marie Boher, Sarah Burdett, Yu‐Hui Chen, Noel W. Clarke, Karim Fizazi, Gwénaëlle Gravis, Nicholas D. James, Glenn Liu, David Matheson, L.R. Murphy, Robert Oldroyd, Mahesh Parmar, Ewelina Rogozińska, Patrick Sfumato, Christopher J. Sweeney, Matthew R. Sydes, Bertrand Tombal, Ian R. White, Jayne F. Tierney - The Lancet Oncology 2023 cited by 89

  22. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

    Authors: Gwénaëlle Gravis, Jean‐Marie Boher, Yu‐Hui Chen, Glenn Liu, Karim Fizazi, Michael A. Carducci, Stéphane Oudard, Florence Joly, David Jarrard, M. Soulié, Mario Eisenberger, Muriel Habibian, Robert Dreicer, Jorge A. García, Maha H.M. Hussain, Manish Kohli, Nicholas J. Vogelzang, Joel Picus, Robert S. DiPaola, Christopher J. Sweeney - European Urology 2018 cited by 247

  23. Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study

    Authors: Claire F. Friedman, John D. Hainsworth, Razelle Kurzrock, David R. Spigel, Howard A. Burris, Christopher J. Sweeney, Funda Meric‐Bernstam, Yong Wang, Jonathan Levy, Jessica M. Grindheim, David S. Shames, Katja Schulze, Arisha Patel, Charles Swanton - Cancer Discovery 2021 cited by 101

  24. MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2–Altered Advanced Solid Tumors

    Authors: Christopher J. Sweeney, John D. Hainsworth, Ron Bose, Howard A. Burris, Razelle Kurzrock, Charles Swanton, Claire F. Friedman, David R. Spigel, Tania Szado, Katja Schulze, Richard Price, Julia Malato, Amy A. Lo, Jonathan Levy, Yong Wang, Wei Yu, Funda Meric‐Bernstam - Journal of Clinical Oncology 2023 cited by 67